Literature DB >> 19383781

Thyroid gene expression in familial nonautoimmune hyperthyroidism shows common characteristics with hyperfunctioning autonomous adenomas.

Aline Hébrant1, Jacqueline Van Sande, Pierre P Roger, Martine Patey, Marc Klein, Claire Bournaud, Frédérique Savagner, Jacques Leclère, Jacques E Dumont, Wilma C G van Staveren, Carine Maenhaut.   

Abstract

CONTEXT: Dominant activating mutations of the TSH receptor are the cause of familial nonautoimmune hyperthyroidism (FNAH) (inherited mutations affecting the whole gland since embryogenesis) and the majority of hyperfunctioning autonomous adenomas (AAs) (somatic mutations affecting only one cell later in the adulthood).
OBJECTIVE: The objective of the study was defining the functional and molecular phenotypes of FNAH and comparing them with the ones of AA.
DESIGN: Functional phenotypes were determined in vitro and molecular phenotypes by hybridization on microarray slides. PATIENTS: Nine patients with FNAH were investigated, six for functional in vitro study of the tissue and five for gene expression.
RESULTS: Iodide metabolism, H(2)O(2), cAMP, and inositol phosphate generation in FNAH slices stimulated or not with TSH were normal. The mitogenic response of cultured FNAH thyrocytes to TSH was normal but more sensitive to the hormone. Gene expression profiles of FNAH and AAs showed that among 474 genes significantly regulated in FNAH, 93% were similarly regulated in AAs. Besides, 783 genes were regulated only in AAs. Bioinformatic analysis pointed out common down-regulations of genes involved in immune response, cell/cell and cell/matrix adhesions, and apoptosis. Pathways up-regulated only in AAs mainly involve diverse biosyntheses. These results are consonant with the larger growth of AAs than FNAH tissues.
CONCLUSIONS: Whether hereditary or somatic after birth, activating mutations of the TSH receptor have the same qualitative consequences on the thyroid cell phenotype, but somatic mutations in AAs have a much stronger effect than FNAH mutations. Both are variants of one disease: genetic hyperthyroidism.

Entities:  

Mesh:

Year:  2009        PMID: 19383781     DOI: 10.1210/jc.2008-2191

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Transcriptome, methylome and genomic variations analysis of ectopic thyroid glands.

Authors:  Rasha Abu-Khudir; Jean Paquette; Anne Lefort; Frederick Libert; Jean-Pierre Chanoine; Gilbert Vassart; Johnny Deladoëy
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

2.  A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas.

Authors:  G Dom; M Tarabichi; K Unger; G Thomas; M Oczko-Wojciechowska; T Bogdanova; B Jarzab; J E Dumont; V Detours; C Maenhaut
Journal:  Br J Cancer       Date:  2012-07-24       Impact factor: 7.640

3.  Severe thyrotoxicosis in an infant revealing familial nonautoimmune hyperthyroidism with a novel (C672W) stimulating thyrotropin receptor germline mutation.

Authors:  Isabelle Oliver-Petit; Frédérique Savagner; Solange Grunenwald; Magaly Vialon; Thomas Edouard; Philippe Caron
Journal:  Clin Case Rep       Date:  2017-10-25

4.  Thyroid follicular adenomas and carcinomas: molecular profiling provides evidence for a continuous evolution.

Authors:  Geneviève Dom; Sandra Frank; Sebastien Floor; Pashalina Kehagias; Frederick Libert; Catherine Hoang; Guy Andry; Alex Spinette; Ligia Craciun; Nicolas de Saint Aubin; Christophe Tresallet; Frederique Tissier; Frederique Savagner; Samira Majjaj; Ilse Gutierrez-Roelens; Etienne Marbaix; Jacques E Dumont; Carine Maenhaut
Journal:  Oncotarget       Date:  2017-12-08

5.  Commentary: Thyrotropin Stimulates Differentiation Not Proliferation of Normal Human Thyrocytes in Culture.

Authors:  Aglaia Kyrilli; Sabine Paternot; Françoise Miot; Bernard Corvilain; Gilbert Vassart; Pierre P Roger; Jacques E Dumont
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-25       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.